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Abstract
Trial design: We present a study protocol for a multi-centre, randomised, double-blind, parallel-group, placebo-
controlled trial that seeks to test the feasibility, acceptability and effectiveness of a 52-week period of treatment
with the first-in-class co-stimulatory blocker abatacept for preventing or delaying the onset of inflammatory arthritis.
Methods: The study aimed to recruit 206 male or female subjects from the secondary care hospital setting across the
UK and the Netherlands. Participants who were at least 18 years old, who reported inflammatory sounding joint pain
(clinically suspicious arthralgia) and who were found to be positive for serum autoantibodies associated with
rheumatoid arthritis (RA) were eligible for enrolment. All study subjects were randomly assigned to receive weekly
injections of investigational medicinal product, either abatacept or placebo treatment over the course of a 52-week
period. Participants were followed up for a further 52 weeks. The primary endpoint was defined as the time to
development of at least three swollen joints or to the fulfilment of the 2010 American College of Rheumatology/
European League Against Rheumatism (ACR/EULAR) classification criteria for RA using swollen but not tender joints,
whichever endpoint was met first. In either case, swollen joints were confirmed by ultrasonography. Participants, care
givers, and those assessing the outcomes were all blinded to group assignment. Clinical assessors and ultrasonographers
were also blinded to each other’s assessments for the duration of the study.
Conclusions: There is limited experience of the design and implementation of trials for the prevention of inflammatory
joint diseases. We discuss the rationale behind choice and duration of treatment and the challenges associated with
defining the “at risk” state and offer pragmatic solutions in the protocol to enrolling subjects at risk of RA.
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Background
Rheumatoid arthritis (RA) is a common chronic inflam-
matory immune-mediated disease of joints afflicting more
than 500,000 subjects in the UK [1, 2]. If not adequately
treated, the condition leads to destruction of synovial
joints and significant disability. RA is costly to individuals
and their families; one third of patients with arthritis stop
work within 2 years of onset because of the deterioration
in quality of life associated with their disease [3]. In the
UK, RA is costly to the economy; the cost is estimated to
be in the region of £5 billion per year through direct costs
to the National Health Service (NHS) and associated
healthcare providers and indirect costs associated with
early mortality and loss of productivity [4].
The introduction of therapeutic strategies that focus
on early, intensive treatment with conventional synthetic
and biological disease-modifying anti-rheumatic drugs
(DMARDs) has transformed the treatment of RA. Clin-
ical trials have demonstrated that this approach leads to
higher proportions of patients achieving periods of sus-
tained clinical remission. This is associated with improved
function and slowing or even prevention of joint damage
over time. Indeed, intensive “treat-to-target” strategies in
patients with very early RA can lead to extended periods
of drug-free remission in a subset of patients [5]. If the
pre-clinical phase of disease could be defined with accur-
acy, targeting therapy to those at highest risk of develop-
ing disease would have the potential to prevent or at the
very least delay the onset of RA. Were such an approach
to be successful, the disabling symptoms and signs of arth-
ritis and the potential risks of unemployment could be
prevented. Furthermore, the development of potentially
life-threatening co-morbidities associated with chronic
inflammatory diseases, such as cardiovascular disease and
infection, could be substantially reduced.
The combination of serum antibodies to citrullinated
protein antigens (ACPAs) and joint pain (termed arthral-
gia), in the absence of clinically detectable synovitis, is
considered to most accurately define subjects at high risk
of progressing to RA [6–8]. Data from longitudinal obser-
vational cohorts indicate that about 40% of high-risk sub-
jects progress to clinically apparent arthritis within 18
months [9]. The combination of IgM rheumatoid factor
(RF) and high serum ACPA levels defines those at highest
risk; recent unpublished data indicate that the risk of
developing disease in subjects with high titre ACPA in the
absence of RF may be comparable to that in ACPA+RF+
subjects [9]. It follows from this that ACPA+RF+ or
ACPA+RF− arthralgia individuals would provide a valid
target population for therapeutic intervention aimed at
prevention of the syndrome we recognise as RA.
Abatacept is a fusion protein composed of the Fc region
of the immunoglobulin IgG1 fused to the extracellular
domain of cytotoxic T-lymphocyte antigen 4 (CTLA-4)
[10]. Specifically, abatacept, a first-in-class co-stimulatory
blocker, is a biologic DMARD that targets immune reac-
tions early in the chain of events leading to inflammation
in RA. It functions by interrupting the interaction between
T cells and antigen-presenting cells, attenuating the co-
stimulatory signals required for T-cell activation, differenti-
ation and effector responses [11]. This results in down-
stream immunomodulatory effects on other inflammatory
cells of the immune system.
In patients with established RA, administration of abata-
cept is associated with statistically significant and clinically
meaningful improvements in the signs and symptoms,
physical function and health-related quality of life. It
inhibits structural damage in a broad spectrum of patients
[12, 13], including those with early or established disease
[14] and those with an inadequate response to tumour
necrosis factor (TNF) blockade [15]. Interestingly, disease
activity scores (DASs) have been shown to continue to
improve beyond 12months, indicating that the beneficial
effects of co-stimulatory blockade not only are sustained
but accumulate over extended periods of time.
In the ADJUST study, abatacept demonstrated good
efficacy in patients with very early RA, including ACPA+
patients with undifferentiated arthritis, delaying onset of
RA when compared with placebo, and promoting sustained
remission rates and reduced radiographic progression, even
after therapy is withdrawn [16]. More recent phase III stud-
ies have confirmed the efficacy of weekly subcutaneous
(SC) injections of abatacept [17]. Clinical efficacy as mea-
sured by American College of Rheumatology 20 (ACR 20)
and Health Assessment Questionnaire (HAQ) response
was similar between SC abatacept and intravenous (IV)
abatacept. Clinical trials and post-marketing surveillance
suggest that the drug has an acceptable safety profile,
particularly with respect to infection.
Although abatacept has a very favourable safety profile,
suggesting that this approach might be acceptable to indi-
viduals during the pre-clinical phase of RA, there were no
published studies at the time of APIPPRA (Arthritis Preven-
tion In the Pre-clinical Phase of RA with Abatacept) study
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protocol development investigating the acceptability of tar-
geted treatment strategies during the pre-clinical phase of
RA. Therefore, understanding the factors that influence the
acceptability of this therapeutic approach and the willing-
ness of at-risk subjects to participate in interventional stud-
ies will be fundamental to trial methodology and the
success of preventative, personalised medicine in the future.
Methods/Design
Study objectives
The principal objective of the study is to determine
whether RA can be prevented or delayed if targeted im-
munotherapy is administered to subjects in whom auto-
antibody screening indicates a high risk of developing
disease. Specifically, this study will test the hypothesis
that the onset of arthritis in an “at risk” group can be
prevented or delayed by weekly injections of abatacept
for a period of 52 weeks.
The specific aims of study are to do the following:
1. Evaluate the feasibility, efficacy and acceptability of
abatacept therapy in subjects at high risk of developing
RA and
2. Characterise immune and inflammatory responses
associated with ACPA before, during and after
therapy with abatacept.
Trial design
The APIPPRA trial is a randomised, placebo-controlled,
double-blind multi-centre trial undertaken at 31 specialist
rheumatology clinics across the UK and the Netherlands.
The trial was designed to ascertain the effectiveness of aba-
tacept in ACPA+RF+ or ACPAhighRF− subjects with arthral-
gia who are deemed to be at high risk of developing RA.
Eligible subjects will be randomly allocated to receive
weekly injections of either abatacept or placebo treatment
over the course of a 52-week period. This provides the best
chance of establishing whether differences observed be-
tween the two groups are due to the treatment.
The SPIRIT checklist is included as (Additional file 4).
The study design is shown in Fig. 1.
Study population
The APIPPRA study will recruit study subjects who are
at high risk of developing RA and who show no clinical
evidence of joint swelling. Participants may be recruited
by using a range of ethically approved methods, including
during rheumatology out-patient clinics, following referral
to recruiting centres from other rheumatology out-patient
clinics, referrals from general practitioner (GP) practices
through the routine referral pathway or patient identifica-
tion centre (PIC) pathway, or through existing research
databases and registries. Subjects may be identified by
pre-screening of laboratory results for RF and ACPA.
Eligibility criteria
Inclusion criteria
1. Male or female subjects who are at least 18 years old.
2. Arthralgia, defined as non-traumatic joint pain local-
ised to synovial joints, including (but not necessarily
confined to) hands, wrists or feet and considered (by
the supervising rheumatologist) to be inflammatory in
nature.
3. Positive for serum RF and ACPA as defined by local
clinical laboratory testing. Subjects who are RF-
negative but who carry high levels of serum ACPA
(defined as being at least 3 × upper limit of normal
[ULN] for the assay) may be included.
4. Able and willing to give written informed consent and
comply with the requirements of the study protocol
(Additional file 1).
Exclusion criteria
Target disease exceptions:
1. Previous diagnosis of RA or other form of
inflammatory arthritis, including (but not limited
to) systemic lupus erythematosus, psoriatic arthritis,
ankylosing spondylitis, gout or pyrophosphate
arthropathy and including current treatment with
DMARDs or biological therapy.
2. Arthralgia that, in the opinion of the supervising
physician, is poorly localised (e.g., pelvic or
shoulder girdle pain, pain that is confined to the
axial skeleton or entheses, or pain which the
physician considers to be due to osteoarthritis or
fibromyalgia or related to other autoimmune
conditions such as type I diabetes, coeliac or
autoimmune thyroid disease).
3. Clinically apparent inflammatory arthritis, as
assessed by a rheumatologist, characterised by
soft tissue swelling of one or more synovial
joints. Subclinical synovitis, as detected by
imaging modalities such as ultrasonography or
magnetic resonance imaging, is not an exclusion
criterion.
4. A history of oral or parenteral use of corticosteroids
within the last 12 weeks used to treat the current
episode of musculoskeletal symptoms.
5. Co-morbidities requiring chronic treatment with
immunosuppressive or immune modulating
therapy.
6. Subjects who have at any time received treatment
with any investigational drug within 28 days of the
first dose of study drug.
7. A history of acute allergic reactions to biological
therapy or immunoglobulins.
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Fig. 1 Study design and flow chart
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Medical history and concurrent diseases:
1. Subjects who are incapable of completing study-
related assessments or give informed consent (see
Additional file 1).
2. Subjects with current symptoms of severe,
progressive or uncontrolled renal, hepatic,
hematologic, gastrointestinal, pulmonary, cardiac,
neurologic or cerebral disease, whether or not
related to RA and which, in the opinion of the
investigator, might place a subject at unacceptable
risk for participation in the study.
3. Subjects with a history of cancer, other than non-
melanoma skin cell cancers cured by local resection
or carcinoma in situ, in the last 5 years.
4. Subjects with tuberculosis (TB), including those at
high risk of TB, chronic viral infections or recent
serious bacterial infections; subjects receiving live
vaccinations within 3 months of the anticipated first
dose of study medication; or those with chronic
illnesses that would, in the opinion of the
investigator, put the participant at risk.
5. Subjects who currently abuse drugs or alcohol.
6. Subjects who are pregnant or breastfeeding or
women of child-bearing potential not willing to use
adequate contraception during the period of investi-
gational medicinal product (IMP) dosing and for up
to 14 weeks after the last dose of study drug.
7. Male subjects not willing to use adequate
contraception during the period of IMP dosing and
for up to 14 weeks after the last dose of study drug.
Physical and laboratory tests at screening Subjects
must not test positive for the following:
1. Latent tuberculous infection according to the
interferon gamma release assay. Subjects who are
positive and who have received treatment for at
least 4 weeks may be selected.
2. Antibodies to hepatitis B surface antigen.
3. Hepatitis C antibody if the presence of hepatitis C
virus was also shown with polymerase chain
reaction or recombinant immunoblot assay.
4. HIV.
Subjects with any of the following laboratory values or
other test results that, in the opinion of the principal in-
vestigator, might place a subject at unacceptable risk for
participation in the study:
1. Haemoglobin < 85 g/L
2. White blood cell count < 3 × 109/L
3. Platelets < 100 × 109/L
4. Serum creatinine > 2 times the ULN
5. Serum alanine transaminase (ALT) or aspartate
aminotransferase (AST) > 2 times the ULN.
Trial intervention
Investigational medicinal product/placebo schedule and
administration
Abatacept will be administered by SC injection at a dose
of 125 mg per injection (125 mg/mL). Placebo is supplied
as identically labelled injections containing a sterile sa-
line solution for SC administration. IMP is supplied as
kits of four pre-filled syringes with coded label. Given
that there are no guidelines or therapies licensed for
treating subjects at risk of RA and that close monitoring
of signs and symptoms until the development of swollen
joints is standard of care, the use of placebo was deemed
to be acceptable in this clinical trial.
Treatment period (weeks 0–52)
Following randomisation, participants will start their dosing
regimen at the baseline visit. Abatacept (or placebo) will be
injected weekly at the recommended dosage of 125mg/mL
for 52weeks. Participants are trained to self-administer
study drug subcutaneously (for the first injection) using the
single-dose pre-filled syringe in accordance with local prac-
tices for the administration of biological therapy as part of
standard care. Participants will be given 3months’ worth of
study medication at baseline and at each subsequent 3
monthly scheduled visits during the first 12months. Partici-
pants will also be given information about the study drug,
such as the Arthritis Research UK (now Versus Arthritis)
Drug Information leaflet, in accordance with local practise.
Subjects will also be given a study medication diary card to
record their weekly injections.
In the event of missed doses, participants should not
take their medication unless it is within ± 3 days of the
scheduled medication dosing date. In addition to the 3
monthly visits, there will be brief telephone consulta-
tions, once a month, to check that study subjects are ad-
ministering their weekly injections and to ask whether
there have been any changes in their symptoms.
Follow-up period (weeks 53–104)
Once participants have completed the 52-week course
of IMP/placebo, they will be seen in the outpatient
clinic every 3 months for assessments (see Table 1;
Schedule of blood and urine sampling) similar to
those in year 1 in order to monitor the impact of the
treatment phase. This follow-up period is especially
important because, if at any time participants develop
new joint pains or swelling, they will be assessed
promptly and treated appropriately in a similar way
that clinical staff would assess any new patient pre-
senting with similar symptoms.
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Concomitant medication
For the duration of the trial, the investigator or another
healthcare professional (for example, GP) may prescribe
simple analgesics or non-steroidal anti-inflammatory
drugs considered necessary for the treatment of the par-
ticipant’s joint symptoms. Treatments for concurrent
Table 1 Trial Flowchart and Schedule of Visits
Assessment Study treatment Follow up
Visit No.a 1 2 3 4 5 6 7 8 9 10
WEEKS Screening Baseline 13 26 39 52 65 78 91 104
Registration Form X
Demographics X
Eligibility checks b X
Medical History X
Physical Examination X X X X X
Disease Activity Assessments X X X X X X X X X
X-rays of hands & feet c Xc
Ultrasonography of symptomatic joints and limited joint set d Xd Xd Xd Xd Xd
ACR/EULAR remission X X X X X X X X X
IMP supply for weekly SC dosing e X X X X
Treatment Log (IMP) X X X X
ESR & CRP f X X X X X X X X X
Routine Bloods (Haem & Biochem) g n Xg X X X X Xn Xn Xn Xn
Screening Bloods (HIV, Hep B& C, TB) c Xc
Chest X-ray c Xc
Lifestyle Factors Questionnaire X X X X X
Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire h Xh Xh
Health Assessment Questionnaire (HAQ) X X X X X X X X X
Modified Illness Perception Questionnaire (IPQ-R) X X X X X
Euro-Quality of Life Questionnaire (EQ-5D) X X X X X
Hospital Anxiety and Depression Scale (HADs) X X X X
Functional Assessment Of Chronic Illness Therapy-Fatigue Questionnaire (FACIT-F) X X X X X
RA Work Instability Scale (RA-WIS) X X X X X
Perceptions of Trial Participation Questionnaire i Xi
Concomitant Medication X X X X X X X X X
Adverse Events X X X X X X X X X
Compliance checks j X X X X
Status Form X X X X X X X X
Withdrawal Form k Xk Xk Xk Xk Xk Xk Xk Xk
Blood/Urine for biomarkers l X X X X X X X X X
aFlexibility of scheduled visits will be allowed of +/- 2 weeks either side of visit
bEligibility criteria
cThese tests can be used if taken up to 12 weeks before screening
dUltrasonography must be done before treatment is initiated at baseline visit and within 2 weeks either side of the scheduled 6, 12, 18 and 24 month Visit
eThree months worth of IMP will be supplied for weekly subcutaneous dosing. Missed doses are only allowed if within ± 3 day window
fThese assessments will not be necessary if the baseline visit is scheduled within two weeks of the screening visit
gThese tests may be undertaken as part of routine assessments
hSPARRA questionnaire will be given to participants to be completed in their own time after the study visit, to be returned to the local study team by post
iPotential participants, including those that do not wish to participate in the APIPPRA study, will complete the Perceptions of Trial Participation Questionnaire
following written consent
jMonthly telephone calls will also be used to address compliance during IMP treatment period
kAs required
lSee Table 2, for schedule of sampling for exploratory biomarkers
mSubjects will be randomised following baseline clinical assessments, ultrasonography and blood/urine samples
nRoutine bloods beyond the 12 month study visit will be taken only if clinically indicated, and left to the discretion of the supervising physician
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non-rheumatic disorders will be given as needed pro-
vided that they are not expected to interfere with the
evaluation of the study medication. However, the follow-
ing drugs are not permitted before the onset of clinically
apparent synovitis (primary endpoint):
 Oral or parenteral glucocorticoids. Short courses (<2
weeks) of oral or parenteral steroids will be permitted
for the treatment of significant, non-rheumatic, con-
current illnesses, including but not confined to
asthma and chronic obstructive pulmonary disease.
 DMARDs.
 Any other biological agent for the treatment of RA.
 Any other medicinal product that, in the supervising
physician’s opinion, may influence underlying
disease activity through effects on immune or
inflammatory responses or both (with the exception
of non-steroidal anti-inflammatory drugs).
Treatment for study subjects reaching primary endpoint
For those study subjects achieving the primary endpoint
(i.e., the development of clinically apparent synovitis or
RA), the use of corticosteroids and DMARDs will be
permitted, and the choice of therapy will be left to the
discretion of the supervising physician. All subjects re-
main in the study and complete follow-up assessments
in accordance with the schedule of visits (see Table 1,
Trial flow chart), including full documentation of treat-
ment for their inflammatory arthritis.
Treatment-stopping rules
The trial may be prematurely discontinued by the sponsor
or chief investigator (CI) on the basis of new safety infor-
mation or recommendations given by the data monitoring
and ethics committee to the trial steering committee. If
the trial is prematurely discontinued, active participants
will be informed, final data will be collected, and no fur-
ther participant data will be collected thereafter. The re-
search ethics committee will be informed within 15 days
of the early termination of the trial.
Study assessments
After screening, all participants will undergo baseline
study visits and then 3 monthly follow-up visits for the
duration of the trial. Clinical assessors will be blinded to
joint assessments by ultrasonography.
Participants will follow the visit schedule summarised
in Table 1 unless participants consider that they are ex-
periencing a worsening of symptoms or have developed
swelling of joints, in which case participants will be seen
within 2 weeks. In addition to attending the 3 monthly
assessments, they will be telephoned by their research
nurse or designated staff involved in the study every
month (during the treatment period) to check that study
subjects are adhering to their study medication and
managing their symptoms. Details of assessments and
flexibility at scheduled visits are shown in Table 1.
The baseline assessment should be performed no later
than four weeks after the screening assessment. For all
subsequent assessments, if participants cannot attend on
the due date, a two-week window either side of the as-
sessment due date will be permitted.
Unscheduled visit assessments
These assessments will be undertaken for subjects ex-
periencing worsening of symptoms or swelling of joints
between scheduled visits. Study subjects will be seen
promptly and usually within two weeks of new signs and
symptoms developing.
1. Physical examination
2. Disease activity (includes extended joint counts 68/
66, DAS28, simple disease activity index (SDAI),
clinical disease activity index (CDAI), pain visual
analogue scale (VAS) and physician and patient
global assessments (VAS))
3. ACR/European League Against Rheumatism (ACR/
EULAR) remission (as defined in [18])
4. Acute-phase reactants: erythrocyte sedimentation
rate (ESR) and C-reactive protein
5. Patient questionnaires as listed above at baseline visit
6. Confirmation of clinically apparent synovitis by
ultrasonography
7. Blood for biomarkers (this will replace the
subsequent scheduled blood draw when the date of
the unscheduled visit precedes the next scheduled
visit by not more than four weeks)
8. Urine for biomarkers (this will replace the
subsequent scheduled urine collection when the
date of the unscheduled visit precedes the next
scheduled visit by not more than four weeks).
Ultrasonography
Participants will also undergo imaging by ultrasonography.
This part of the APIPPRA study will be undertaken in those
recruiting centres that provide this service as part of routine
clinical care and/or where there are personnel trained in
musculoskeletal ultrasound using imaging equipment
approved by the APIPPRA study investigators (e.g., probes
with a frequency of at least 12 mHz and acceptable power
Doppler sensitivity). All participating ultrasonographers
were mandated to undertake study-specific training.
Scans will be performed at baseline and 6, 12, 18 and
24months (and at any point between where the super-
vising physician believes that the study subject has
achieved the primary endpoint). At each scanning visit,
designated sonographers will scan a core set of joints in-
cluding (but not confined to) dorsal views of the wrists,
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metacarpophalangeal (MCP 1–3), proximal interphalan-
geal (PIP 2, 3) and metatarsophalangeal (MTP 2–5)
joints. Grading of grayscale and power Doppler mea-
surements will be documented by applying semi-
quantitative scales dictated by atlases provided to each
participating centre. The scanning process will be sched-
uled before treatment is initiated for the baseline scan,
and within 2 weeks either side of scheduled 6-, 12-, 18-
and 24-month visits, if scans cannot be accommodated
at the same time as scheduled visits.
In addition to the above assessments, ultrasound evalu-
ation will be performed to confirm whether the study sub-
ject has met the primary outcome and will include the
core set of joints, as above, as well as imaging of any
additional symptomatic joints. Ultrasound assessments
and scores will be added to the electronic case report form
upon completion of the imaging study and scores will be
blinded to the supervising PI or clinical assessor. Anon-
ymised copies of images will be either stored on CDs and
securely mailed or sent electronically to a secure email
address in a central unit so that scores can be reviewed to
ensure consistency of assessments across centres.
X-ray imaging
All x-ray images will be uploaded onto a dedicated,
password-protected web-based system and will be
scored centrally.
Routine clinical laboratory tests
Study subjects will undergo routine blood monitoring to
screen for biological therapy-related toxicity at all assess-
ments or in accordance with local practice if more fre-
quent. Routine blood monitoring beyond the 12-month
study visit will be taken only if clinically indicated and
will be left to the discretion of the supervising physician.
Exploratory laboratory tests
These assays will be undertaken by the study investigators
or designated collaborators either within or outside of the
UK, as agreed and designated by the APIPPRA study inves-
tigators. Samples of blood and urine will be transported
from recruiting sites across the UK and the Netherlands to
pre-designated laboratories based in academic centres for
processing and storage. Subsequently, all samples will be
shipped from processing hubs in batches to the UK Biocen-
tre for long-term storage prior to distribution to the rele-
vant research laboratory for subsequent biomarker analysis
as outlined below. The schedule of blood and urine sam-
pling is summarised in Table 2.
Study endpoints
Primary endpoint
The primary endpoint of this study is the time to devel-
opment of clinical synovitis or RA defined by one of the
following methods, whichever is met first:
1. The time to development of clinically apparent
synovitis in at least three joints, as determined by
two independent assessors with experience in
clinical assessment of RA.
2. The time to development of RA according to the
ACR/EULAR 2010 classification criteria [19], where
joint involvement is defined as joint swelling. The
ACR/EULAR 2010 classification criteria for RA
redefines previous paradigms of RA by focusing on
features at earlier stages of disease that best
discriminate those features associated with
persistent and/or erosive disease from those that do
not. They were defined by consensus with the aim
of identifying a disease state for which starting
disease-modifying therapy was deemed appropriate.
For either endpoint, joint swelling will be confirmed
by ultrasonography (Fig. 2). If the primary endpoint is
not confirmed, study participants continue IMP.
Secondary endpoints
The secondary endpoints of this study are the following:
Table 2 Schedule of blood and urine sampling
Biological Sample Type & No. Tube Cap Colour Baseline Weeks
13
Weeks
26
Weeks
39
Weeks
52
Weeks
65
Weeks
78
Weeks
91
Weeks
104
Serum SST x 2 Red 18mla 18ml 18ml 18ml 18ml 18ml 18ml 18ml 18ml
PBMC Heparin x 5 Green 40ml 40ml 40ml 40ml 40ml 40ml 40ml 40ml 40ml
RNA Tempus x 2 Blue 5ml 5ml 5ml 5ml 5ml 5ml 5ml 5ml 5ml
DNA EDTA x 1 Purple 7ml
Routine drug monitoringb According to local procedures 10ml 10ml 10ml 10ml 10ml 10ml 10ml 10ml
Urine Plain x 1 Beige 20ml 20ml 20ml 20ml 20ml 20ml 20ml 20ml 20ml
Total volume of blood draw 70ml 73ml 73ml 73ml 73ml 73ml 73ml 73ml 73ml
areflects volume of whole blood draw into sample specific tubes
bup to 20 mls will be collected
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1. The development of RA according to the ACR/
EULAR 2010 criteria where joint involvement
based on ultrasound assessments will be
included.
2. Assessments of disease activity and progression
over time, including the following:
 DAS28 (tender and swollen joint counts, patient
global VAS, and ESR) and extended joint count
68/66
 SDAI and CDAI
 Pain VAS
 Lifestyle Factors Questionnaire, HAQ,
Modified Illness Perception Questionnaire
(Modified IPQ) and Euro-Quality of Life
Questionnaire (EQ-5D)
 Hospital Anxiety and Depression Scale (HADS)
 RA–Work Instability Scale (RA-WIS)
 Functional Assessment of Chronic Illness
Therapy–Fatigue Questionnaire (FACIT-F)
 Symptoms in Persons At Risk of Rheumatoid
Arthritis (SPARRA) questionnaire
3. The proportion of participants requiring DMARD
therapy and the time to commencing DMARD
therapy, including oral or parenteral
corticosteroids
4. Progression of radiographic changes in x-rays of the
hands and feet scored by van der Heijde–Sharp
Modified Scores or using the Larsen score
5. Changes in scores of synovitis and vascularity defined
by ultrasonography and power Doppler over time
6. Adverse events
7. A Perceptions of Trial Participation
Questionnaire was also included to gain insights
into the acceptability of this therapeutic
approach.
Exploratory endpoints
1. Changes in serum ACPA levels over time
2. ACPA isotype and antigenic fine specificity over time
3. Signatures of immune and inflammatory responses
as defined through analysis of serum, peripheral
blood cell subsets, peripheral blood RNA expression
profiling and urine.
The focus of the proposed biomarker analysis is twofold.
First, autoantibody profiles, immune cell phenotyping and
gene expression signatures will be interrogated to identify
novel signatures associated with a high-risk state. This
could be used to stratify patients for future prevention stud-
ies. Second, we will use similar assays to better understand
the mechanisms whereby study subjects respond to
abatacept.
Statistical considerations
Randomisation procedure, blinding and data management
If the participant is willing to participate in the trial, in-
formed consent will be obtained at the start of the screen-
ing visit (Additional files 1 and 2). Screening assessment
data will be entered by sites onto a web-based InferMed
MACRO Electronic Data Capture (EDC) system hosted
on a dedicated secure website by King’s College London,
using only the participant’s initials and date of birth as
identifiers (Additional file 3). The EDC system will auto-
matically assign a unique participant identification num-
ber (PIN) to each participant as they are registered onto
the EDC system. Participants who consent to screening
but who are subsequently found to be ineligible will also
be recorded in the EDC system for CONSORT (Consoli-
dated Standards of Reporting Trials) reporting purposes.
These procedures will operate in accordance with the
Fig. 2 Primary endpoint roadmap
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International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Hu-
man Use guidelines for good clinical practice (GCP),
meeting the requirements of the Medicines and Health-
care products Regulatory Agency.
Once participants are confirmed eligible, authorised
study site staff will access the web-based randomisation
system and enter the PIN, initials and date of birth of
the participant along with details of any characteristics
to be used in the randomisation algorithm. Staff at indi-
vidual centres and the sponsor will be unaware of the
allocation sequence.
Participants will be randomly assigned to IMP (abata-
cept) and placebo groups by using the method of strati-
fied randomisation with randomly permuted blocks
within strata defined by gender, country (UK and the
Netherlands) and smoking status (never, previous and
current). Once the participant is randomly assigned, the
system will automatically recognise what active and pla-
cebo kit numbers are available in the site pharmacy and
will select four blinded treatment kit numbers from the
appropriate trial arm and this will be allocated to the
participant. At each follow-up visit, site staff will again
access the randomisation system and allocate new treat-
ment kits for the participant. All participants and staff
involved in the conduct of the study will be blind to
treatment allocation throughout the trial.
Assessment of safety
All subjects who receive study drugs will be evaluated for
safety. Safety outcomes include adverse events, clinically
significant changes in vital signs, laboratory test abnormal-
ities, and clinical tolerability of the drug. The investigator
will determine the severity of each adverse event as mild,
moderate, severe or very severe. Laboratory findings that
the investigator feels are clinically relevant will be re-
corded as adverse events. In addition, the investigator will
determine the relationship of the adverse event to the ad-
ministration of the study drug. Any occurrence of a ser-
ious adverse event (SAE) from time of consent forward,
up to and including follow-up visits, will be reported.
Sample size
Using time to development of arthritis as the primary out-
come, or development of RA within 24months of follow-
up, according to 2010 ACR/EULAR criteria, a total of 52
study subjects need to present with this endpoint from
206 randomly assigned, based on the following informa-
tion. It is conservatively anticipated that 40% of partici-
pants on placebo will develop arthritis. A sample size of
172 subjects would be needed to provide 80% power to
detect a 50% relative reduction to 20% in the abatacept
arm (a hazard ratio of 0.437) on the basis of a two-sided
log-rank test at the 5% level of significance without loss to
follow-up of any of the required 52 events. Therefore, 206
subjects (103 per arm) will be randomly assigned to allow
for loss of events due to dropout, applying a conservative
20% inflation for dropout.
Similar effect sizes are detectable for binary outcomes
and for other time-to-event and proportion outcomes
such as the development of RA according to ACR/EULAR
2010 criteria alone. For continuous secondary outcomes,
such as DAS measures, a medium effect size difference in
means (of size 0.5 of a standard deviation, or SD) between
the arms, based on the two-sided unpaired t test at the 5%
significance level, can be detected with 85% to 90% power
if 146 to 172 subjects are followed up. In view of the num-
ber of required secondary outcomes, with 172 participants
followed up, there is also 80% power to detect medium-
sized effects in secondary outcomes (0.52 of a SD) using a
secondly applied significance level of 1%. Analyses incorp-
orating baseline adjustment or repeated measures data (or
both) will provide increased precision.
In view of the large number of secondary outcomes and
the fact that the sample size was not set to detect powered
effects specifically on the scale of these secondary mea-
sures, the use of a 1% level of significance goes only part-
way towards addressing the fact that multiple testing
increases the chance that significant secondary findings
are false. The results from secondary outcome analyses
will be interpreted cautiously and in relation to the esti-
mated confidence limits on the actual scale of the mea-
sures. Significance tests will be used sparingly and
restricted where possible to address the stated hypotheses.
Results that are significant in isolation will be interpreted
less strongly than the set of results that are mutually sup-
portive or that support the corresponding primary out-
come or that are supported in previous research findings.
Withdrawal of subjects
Participants will be free to withdraw at any time. Partici-
pants who do withdraw from IMP will be invited to re-
turn for milestone assessments (at months 3, 6, 9 and 12
or at months 15, 18, 21 and 24, depending on the phase
of the study) so that data may be collected and changes
in their disease can be assessed; it will be made clear to
them that this is entirely at their own discretion.
Subjects will discontinue investigational product (and
non-investigational product at the discretion of the
investigator) for any of the following reasons:
1. Withdrawal of informed consent (subject’s decision
to withdraw for any reason) (Additional files 1 and 2).
2. Any clinical adverse event, laboratory abnormality,
or intercurrent illness which, in the opinion of the
PI, indicates that continued participation in the
study is not in the best interest of the subject.
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3. In the PI’s opinion, the need to administer
concomitant medication not permitted by the trial
protocol.
4. Pregnancy.
All subjects who discontinue should comply with
protocol-specified follow-up procedures. The only ex-
ception to this requirement is when a subject withdraws
consent for all study procedures or loses the ability to
consent freely. If a subject withdraws before completing
the study, the reason for withdrawal will be documented
appropriately.
Statistical analysis
The primary analysis approach will be an intention-to-
treat (ITT) strategy, including sensitivity analysis for
missing data [20], sensitivity analysis for low compliance
[21], and sensitivity analysis for use of forbidden rescue
medication or potential informative dropout (described
in the detailed statistical analysis plan).
For each time-to-event outcome, including the primary
outcome, Kaplan–Meier survival curves will be estimated.
A Cox stratified proportional hazards regression model,
accounting for the randomisation stratifiers in the form of
nominal categorical variables, will be used to compare
randomised arms and obtain an estimated hazard ratio for
the treatment effect with 95% confidence interval. Partici-
pant follow-up is on a three-monthly basis, and there will
be additional monthly phone calls when participants are
able to additionally report on their progress. Days will be
the unit of time within the model in order to fully capture
the inevitable variation in the time from baseline to
monthly contacts and to ascertained outcome events.
Each participant who drops out will be included in the
analysis and will be assumed not to have the event and be
censored at the point of dropout. Time will also be cen-
sored for those reaching the 24-month follow-up without
an event. Those with an event will not contribute any fur-
ther time after the event. For the primary outcome, sensi-
tivity analysis will be carried out. This includes an analysis
assuming that those who have dropped out for reasons
connected with disease severity are alternatively deemed
to have had the event and an analysis assuming this alter-
native for those having experienced two affected joints.
For each binary outcome, a stratified difference in pro-
portions using the Cochran–Mantel–Haenszel method will
be used to compare arms accounting for the randomisation
stratifiers in their nominal categorical form. For each con-
tinuous outcome, including DAS28, differences in the mean
of the outcome between arms will be estimated by using a
linear mixed effects regression model of the repeated
measures of the outcome across follow-up. ‘Visit’ will be in-
cluded in the model as a continuous covariate with full
polynomial terms equivalent to including ‘Visit’ as a
categorical factor. Outcome data will be included from the
regular visits and from times of measurement, including at
ultrasound visits. The model will have a heterogeneous
variance first-order autoregressive covariance structure,
where measurements at the non-regular visits are included
in the variance part of the model at the nearest visit and
are included in the mean part of the model in proportion
to how the measurement was timed between two visits.
The ‘visit’ covariate will be located with an origin at 24
months, so that the model with the interactions of the
‘time’ terms with the other included main effect covariates
of study arm, the randomisation stratifiers, and the baseline
of the outcome and its missing indicator will directly pro-
vide the estimate of the study arm effect and its standard
error. The missing indicator method [21] will be used to
enable those participants having any outcome data, but
with missing baseline data, to contribute to the estimate.
Descriptive statistics will be reported for measures of ac-
ceptability, feasibility and safety. Percentage measures will
be reported with exact 95% confidence intervals. There is
no plan to have stopping rules. It is anticipated that the
data monitoring committee (DMC) will request interim
data on safety and will advise on further data required for
monitoring and on trial statistician blinding status. A de-
tailed statistical analysis plan will be developed from the
study protocol prior to the availability of follow-up data
for approval by the independent trial steering committee
(TSC). The primary analysis will follow the ITT principle;
that is, participants will be analysed in the groups to which
they were randomly assigned irrespective of treatment re-
ceived, using all available follow-up data from all ran-
domly assigned participants, with a per-protocol analysis
of compliers only, as defined in the statistical analysis plan.
Alterations to the statistical analysis plan will require re-
approval from the TSC.
Trial oversight
An independent DMC will assess the trial’s progress, oc-
currence of adverse events and all other aspects. It will
comprise a committee chair, the APIPPRA study trial
statisticians, one independent statistician, and at least
two independent members with experience in RA trials.
The DMC will also be responsible for monitoring evi-
dence of harm and for reviewing decisions relating to all
aspects of safety reporting. They will meet prior to initi-
ation of the study and at about 6 monthly intervals, or
at more frequent intervals as deemed appropriate, for
the duration of the study. The statistical analytical plan
will be used to guide decision making.
The TSC was formed to provide oversight of this trial
and ensure that it is being conducted in accordance with
the principles of GCP and the relevant regulations. The
TSC will approve the trial protocol and any protocol
amendments and will provide advice to the investigators
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on all aspects of the study. The TSC will include an inde-
pendent chair, the CI and core study team, an independ-
ent statistician, at least two clinicians with experience in
RA trials who are not otherwise involved in the study, and
an experienced patient expert as patient representative.
The TSC is the main decision-making body and will be
responsible for trial conduct and scientific direction and
will ensure that the study objectives are achieved in a
timely fashion and within budget.
Data management
InferMed MACRO EDC will be used in this study. The
King’s Clinical Trials Unit (KCTU) has extensive experience
with this system. Password management and data exports
will be controlled by the KCTU. No outcome data will be
exported without the explicit consent of the trial statisti-
cian. Changes to the EDC system once the study has begun
will be minimised and will be undertaken only with the full
agreement of the trial statistician, CI and the KCTU where
it is essential to the successful conduct of the study.
Direct access to source data and documents
Site investigator(s) will permit trial-related monitoring,
audits, and regulatory inspections (where appropriate)
by providing the sponsors and regulators with direct ac-
cess to source data and other documents (e.g., hospital
case notes, electronic patient records, completed forms
and questionnaires, and the investigator site file). All
reasonable precautions to maintain the confidentiality of
participants’ identities and protect the integrity of the
data will be taken.
Quality assurance
This trial will be monitored to ensure compliance with
the trial protocol, GCP and all applicable regulations
and to protect scientific integrity. Study management
staff will undertake routine quality-control checks of the
data. This will include additional central and site-based
data checking to ensure that the data quality is accurate.
Data queries will be raised, responded to and closed
within the EDC system. Range and validation checks will
be programmed into the EDC system to minimise tran-
scription errors. Source data verification checks under-
taken onsite will be documented to ensure that the final
dataset has not been amended after checks have been
completed. Checks of randomisation data will be under-
taken periodically to identify any errors. Prior to data-
base lock, all SAEs reported via fax or email will be
cross-checked with the EDC system to ensure that all
are present in the analysis dataset. Any data issues iden-
tified by the trial statistician during preparation of DMC
reports will be reported to the trial coordinator and sys-
tematically rectified across the dataset, through either
central or site data checks.
Discussion
This study protocol describes a secondary prevention
strategy for a common immune-mediated inflammatory
disease targeting a phase of the disease process for which
there is currently no recognised treatment. The trial will
recruit one of the largest populations of “at risk” subjects
to a randomised clinical trial described to date.
The APIPPRA study, designed by clinicians, experi-
enced trialists and patients, is unusual in several re-
spects. Rather than testing the acceptability and efficacy
of an unlicensed IMP in a population of patients with
established disease, this study will explore the effects of
a licensed biologic DMARD in a population of otherwise
healthy individuals deemed to be at risk of developing
RA [22]. When the study was first conceived, the pheno-
type of at-risk subjects was only beginning to emerge. In
2012, a EULAR working group published recommenda-
tions describing the natural history of RA, highlighting
how each phase of the disease corresponded to distinct
clinical and laboratory characteristics [23]. These recom-
mendations were informed in part by longitudinal obser-
vational studies of at-risk subjects. These and many
other studies have been pivotal to stratifying those at
highest risk [22, 24–27], in whom therapeutic interven-
tion is considered to be appropriate, and have provided
a framework for estimating progression rates and for
computing sample size calculations for our study.
The armamentarium for treating established RA has
grown substantially over the last two decades, and this, to-
gether with intensive, target-driven treatment strategies [1,
5, 28], has had a major impact on disease outcomes; remis-
sion rates have approached 40% within 6months of com-
mencing therapy. There is growing appreciation, however,
that the efficacy of interventions may depend on the spe-
cific phase of the disease (reviewed in [29]). For example, it
remains to be determined whether targeting inflammatory
cytokines during the pre-clinical phase of RA at a time
when the inflammatory burden of disease is minimal
would be as beneficial as immunomodulatory drugs. Clin-
ical trials of corticosteroids, for example, have not demon-
strated durable clinical outcomes in the at-risk population
[30–32]. Co-stimulatory blockade with abatacept targets
one of the earliest phases of the disease process—attenuat-
ing de novo activation of self-reactive T cells by antigen-
presenting cells. Abatacept has proven efficacy in early and
established RA, but the drug has never been tested in sub-
jects prior to the onset of clinically apparent arthritis.
Nonetheless, the presence of disease-associated autoanti-
bodies in serum indicates that the autoimmune process
has already started and so we hypothesise that interrupting
these immune reactions with abatacept is a biologically
plausible approach. Furthermore, there are currently no
other licensed therapies available with a comparable safety
profile that target adaptive immunity. Finally, the duration
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of IMP exposure used in the APIPPRA study is largely em-
pirical. Clinical trials of abatacept in patients with recent-
onset type I diabetes, however, have documented durable
outcomes beyond the period of therapy, suggesting that
immune modulation might be more profound, or sus-
tained, if used at the earliest detectable point in the disease
course [33]. Whether co-stimulatory blockade induces im-
munological tolerance, on the other hand, requires further
investigation.
The primary endpoint of the APIPPRA trial is the time
to the development of clinically swollen joints or fulfil-
ment of the 2010 ACR/EULAR classification criteria for
RA, whichever endpoint is met first. Three swollen
joints were chosen for the first primary outcome since
this was the median number of swollen joints identified
from cohorts of at-risk subjects at the time of develop-
ment of clinically apparent arthritis [9]. In routine prac-
tice, this is very often the point in the disease course
when physicians see patients with inflammatory arthritis
for the first time. The validity of the 2010 ACR/EULAR
classification criteria for RA is underpinned by an
intention to treat with disease-modifying drugs [19] and
so including these criteria as a co-primary outcome (by
achieving a score of at least 6) reduces the risk of expos-
ing study subjects to placebo, or to IMP that has proven
inadequate to suppress signs and symptoms, at a time
when standard therapy for new-onset RA would be
deemed appropriate by the supervising physician. Clin-
ical assessments are notoriously subjective, especially
when inflammatory joint disease is in the very earliest
stages. To define primary endpoints with precision, we
opted to confirm the presence of synovitis in clinically
swollen joints by ultrasonography. For these imaging
assessments and for the duration of the study, clinical
assessors and ultrasonographers are blinded to each
other’s joint scores to limit bias. For consistency of scor-
ing, all ultrasonographers undergo study-specific train-
ing and have access to a reference atlas of images for all
joints to be assessed.
A key outcome of the APIPPRA study will be to
determine whether intervention at this phase of the
disease is considered to be acceptable to the high-risk
subject. To this end, we have included as part of
study assessments questionnaires that probe in more
detail people’s perception of risk. We anticipate that
the APIPPRA study will allow us to better define the
at-risk state on the basis of data we acquire from
questionnaires that probe deeper into clinical pheno-
types, from the monitoring of images of symptomatic
joints by ultrasound over time, and from immune
phenotypes acquired from analysis of biological sam-
ples. This information then can be exploited in future
studies to identify those most likely to progress over
pre-defined time periods, on the one hand, while
minimising exposure of individuals to an intervention
they may never need.
Trial status
The APIPPRA study trial received ethical approval on
13 March 2014. The first study subject was randomly
assigned in January 2015, and the trial completed re-
cruitment at end of December 2018 (Additional file 3).
Protocol version
The protocol published here is version 3.2, dated 22
March 2018.
Additional files
Appendices 1: Informed consent form. (PDF 111 kb)
Appendices 2: Informed consent form for additional blood.
(PDF 102 kb)
Appendices 3: Additional information. (DOCX 23 kb)
Additional file 4: SPIRIT (Standard Protocol Items: Recommendations
for Interventional Trials) 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOCX 54 kb)
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